Alucent Biomedical Overview
- Year Founded
-
2014
- Status
-
Out of Business
- Employees
-
20
- Latest Deal Type
-
Out of Business
Alucent Biomedical General Information
Description
Operator of a biomedical company intended to transform the way vascular disease is treated. The company offers biomedical technology that uses photoactivated protein linking to potentially restore vessels and offer durable patency to address the unmet need of patients with difficult-to-treat peripheral artery disease, enabling healthcare professionals to treat their patients and improve their lives.
Contact Information
Website
www.alucentbiomedical.comCorporate Office
- 675 Arapeen Drive
- Suite 102
- Salt Lake City, UT 84108
- United States
Corporate Office
- 675 Arapeen Drive
- Suite 102
- Salt Lake City, UT 84108
- United States
Alucent Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Dec-2025 | Completed | Out of Business | |||
| 4. Later Stage VC (Series B1) | 20-Apr-2023 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 30-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | $24.6M | $25M | Completed | Pre-Clinical Trials | ||
| 1. Angel (individual) | 26-Jan-2015 | $400K | $400K | Completed | Pre-Clinical Trials |
Alucent Biomedical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 48,348,655 | $0.001000 | $0.05 | $1 | $1 | 1x | $1 | 28.1% |
Alucent Biomedical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alucent Biomedical Patents
Alucent Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250186800-A1 | Light-fiber catheter with calibrated output and methods | Pending | 07-Dec-2023 | ||
| WO-2023239950-A1 | Coated balloon catheter for treating arteriovenous fistula and methods for using same | Inactive | 10-Jun-2022 | ||
| US-20230398334-A1 | Coated balloon catheter for treating arteriovenous fistula and methods of using same | Inactive | 10-Jun-2022 | ||
| US-20230405351-A1 | Sterilizable catheter and light fiber for use therewith and methods of sterilization | Pending | 10-Jun-2022 | ||
| WO-2023239948-A1 | Sterilizable nvs catheter and light fiber for use therewith and methods of sterilization | Inactive | 10-Jun-2022 | A61N5/062 |
Alucent Biomedical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alucent Biomedical FAQs
-
When was Alucent Biomedical founded?
Alucent Biomedical was founded in 2014.
-
Where is Alucent Biomedical headquartered?
Alucent Biomedical is headquartered in Salt Lake City, UT.
-
What is the size of Alucent Biomedical?
Alucent Biomedical has 20 total employees.
-
What industry is Alucent Biomedical in?
Alucent Biomedical’s primary industry is Biotechnology.
-
Is Alucent Biomedical a private or public company?
Alucent Biomedical is a Private company.
-
What is Alucent Biomedical’s current revenue?
The current revenue for Alucent Biomedical is .
-
How much funding has Alucent Biomedical raised over time?
Alucent Biomedical has raised $71.2M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
